Back to top


Washington, D.C., USA

SICPA Contributes to a World Bank Pilot Project to Fight Falsified and Sub-Standard Medicines

Marking a further step in the cooperation between SICPA and International Organisations, Anne-Marie Leroy, Senior Vice President and General Counsel of the World Bank Group, and Pierre Viaud, Senior Director Public Affairs & Government Relations of SICPA, signed an agreement today confirming SICPA’s contribution to a Pilot Project developed by the Global Forum on Law, Justice and Development (GFLJD).

This Pilot is a preliminary phase of a larger initiative to fight falsified and substandard medicines in developing countries.

Partnering initially with one country, the project will include assessment of national, cross-border and regional legal and regulatory frameworks. The project builds on the knowledge developed by the World Health Organization, other international actors and on international conventions such as the United Nations Convention against Transnational Organized Crime, and the MEDICRIME Convention of the Council of Europe. SICPA, a Swiss-based private company, is a global provider of secured authentication, identification and traceability solutions and services.

The Pilot Project will be implemented by the World Bank in collaboration with the United Nations Interregional Crime and Justice Research Institute (UNICRI), the International Development Law Organization (IDLO), and the O’Neill Institute for National and Global Health Law at Georgetown University. It paves the way for legal support for the fight against counterfeit medicines in a large number of developing countries.

For more information:

The World Bank:

Global Forum on Law, Justice and Development:

International Development Law Organization:

O’Neill Institute on National and Global Health Law:

United Nations Interregional Crime and Justice Research Institute:




For more information about SICPA and our solutions please contact us.